Our ambition to continuously improve as an organisation and provide sustained value to society has resulted in the creation of a valuable intellectual property portfolio. We possess close to 500 individual patents across nearly 80 patent families. At Centrient, we do not believe in limiting the transfer of essential healthcare technologies between parties. We therefore actively enforce our patents to ensure our customers have full freedom to operate. As such, our customers can rest assured of the reliable delivery of our products without unexpected legal complications resulting from potential patent infringements. Through licence agreements, we provide partners with non-exclusive, worldwide licences for certain patents, and grant them the freedom to operate, develop and commercialise their products. With these agreements, Centrient enables its partners to produce new enzymes that support the sustainable manufacturing of antibiotics.